By Ryan Davis ( October 12, 2018, 6:40 PM EDT) -- The Federal Circuit on Friday affirmed decisions by a Delaware federal judge and the Patent Trial and Appeal Board that patents on Teva's blockbuster multiple sclerosis drug Copaxone are invalid, a win for a slew of generics makers that could cost Teva billions of dollars....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.